Monoamine system disruption induces functional somatic syndromes associated symptomatology in mice
| Autor: | Yuuka Takebayashi, Ryutarou Azuma, Yukinori Nagakura, Shuhei Murai, Masaya Miwa, Nana Ohsaka, Saeri Takahashi, Saori Kawasaki, Hiroko Saito |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Central Nervous System
Male Pain Threshold 0301 basic medicine medicine.medical_specialty Reserpine Central nervous system Experimental and Cognitive Psychology Endogeny Drug Administration Schedule Body Temperature Mice 03 medical and health sciences Behavioral Neuroscience 0302 clinical medicine Internal medicine Intestine Small medicine Animals Blepharoptosis Biogenic Monoamines Gastrointestinal Transit Muscle Skeletal Somatoform Disorders Irritable bowel syndrome business.industry Body Weight Skeletal muscle medicine.disease Small intestine Peripheral 030104 developmental biology Monoamine neurotransmitter medicine.anatomical_structure Endocrinology business Locomotion 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Physiology & Behavior. 194:505-514 |
| ISSN: | 0031-9384 |
| DOI: | 10.1016/j.physbeh.2018.07.007 |
| Popis: | Functional somatic syndromes (FSS), a clinical condition manifesting a variety of unexplained somatic symptoms, has been proposed as an inclusive nosology encompassing individual syndromes such as fibromyalgia syndrome and irritable bowel syndrome. Accumulating evidence suggests that disturbance of the endogenous monoamine system could be involved in the aetiology of FSS. Therefore, the purpose of present study was to investigate whether the disturbance of the monoamine system would cause FSS-associated symptomatology in mice. The optimal dose of reserpine, an inducer of endogenous monoamines reduction, was first explored in mice. General body condition (body weight, rectal temperature, and ptosis) and FSS-associated symptomatology (paw withdrawal threshold, small intestinal transit, and locomotor activity) were measured. The concentration of monoamines was measured in central and peripheral tissues. Mice dosed with reserpine (0.25 mg/kg s.c., once daily for 3 consecutive days) exhibited a decrease in paw withdrawal threshold, delay in small intestinal transit, and reduction of locomotor activity without deterioration of general body condition on day 5 after the first reserpine injection. The concentration of monoamines was decreased in the central nervous system and skeletal muscle, but not in the small intestine. A reserpine dose of 0.5 mg/kg or more caused deterioration of general body condition. In conclusion, the optimal protocol of reserpine treatment for inducing pain symptom without deterioration of general physical condition is 0.25 mg/kg s.c., once daily for 3 consecutive days in mice. This protocol causes not only pain but also FSS-associated symptomatology which are associated with disruption of the endogenous monoamine system. The reserpine-treated animal may be useful for the research of not only fibromyalgia syndrome but also FSS, especially for the research focusing on the hypothesis that FSS is associated with the disturbance of endogenous monoamine system. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect